Recent News

• 01.15.2026 - APYX MEDICAL CORPORATION REPORTS PRELIMINARY, UNAUDITED, FOURTH QUARTER AND FULL YEAR 2025 REVENUE RESULTS
• 01.15.2026 - Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
• 11.20.2025 - APYX MEDICAL CORPORATION ANNOUNCES PRICING OF $10 MILLION PUBLIC OFFERING OF COMMON STOCK
• 11.19.2025 - APYX MEDICAL CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
• 11.19.2025 - APYX MEDICAL CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
• 10.28.2025 - APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR CONFERENCES
• 10.28.2025 - APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS ON NOVEMBER 6, 2025
• 10.13.2025 - Apyx Medical Corporation Submits FDA 510(k) for Device Label Expansion of AYON Body Contouring System™ for Power Liposuction
• 08.12.2025 - APYX MEDICAL CORPORATION TO PARTICIPATE IN THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE

Recent Filings

• 12.16.2025 - EFFECT Notice of Effectiveness
• 12.12.2025 - 8-K Current report
• 12.01.2025 - S-3 Registration statement under Securities Act of 1933
• 11.19.2025 - 8-K Current report
• 11.19.2025 - EX-99.1 EX-99.1
• 11.18.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.17.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]